Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Aditi Sharma, Maria E Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam, Prince Otchere
{"title":"Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study.","authors":"Aditi Sharma, Maria E Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam, Prince Otchere","doi":"10.1186/s40959-025-00319-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardiotoxic effects and therefore requires cardiotoxicity monitoring via serial transthoracic echocardiograms (TTEs). We aimed to evaluate risk factors for trastuzumab related cardiac dysfunction in a South Texas population that is uniquely a majority Hispanic population.</p><p><strong>Methods: </strong>A retrospective study was conducted of female patients with HER2-positive breast cancer who received trastuzumab treatment from 2015 to 2021. A total of 180 patients were identified. Patients without a baseline TTE and a baseline left ventricle ejection fraction (LVEF) less than 53% were excluded. The final sample size included 132 patients. Cardiac dysfunction was defined as a drop in LVEF by more than 10% to less than 53% during the 1-year study period.</p><p><strong>Results: </strong>The incidence of cardiac dysfunction was 6% in the study population. Hispanic/Latino patients composed 58% of the study population and represented 50% of patients who experienced cardiotoxicity. Of the patients who developed cardiotoxicity, 50% had hypertension, 25% had hyperlipidemia, 12.5% had type 2 diabetes mellitus, and 12.5% had previous coronary artery bypass grafts. A total of 12.5% had a history of radiation, 25% had a history of anthracycline therapy, 37.5% were former smokers, and 25% were former alcohol users.</p><p><strong>Conclusions: </strong>The incidence of trastuzumab-related cardiotoxicity in this Hispanic/Latino majority-minority population was 6%, which is surprisingly lower than the 9% cardiotoxicity rate observed in a predominantly white population in a previous study by Otchere et al., in 2023. Further studies are needed to determine the factors contributing to the reduced cardiotoxicity rate observed in this Hispanic population.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"23"},"PeriodicalIF":3.2000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11852898/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardio-oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40959-025-00319-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardiotoxic effects and therefore requires cardiotoxicity monitoring via serial transthoracic echocardiograms (TTEs). We aimed to evaluate risk factors for trastuzumab related cardiac dysfunction in a South Texas population that is uniquely a majority Hispanic population.

Methods: A retrospective study was conducted of female patients with HER2-positive breast cancer who received trastuzumab treatment from 2015 to 2021. A total of 180 patients were identified. Patients without a baseline TTE and a baseline left ventricle ejection fraction (LVEF) less than 53% were excluded. The final sample size included 132 patients. Cardiac dysfunction was defined as a drop in LVEF by more than 10% to less than 53% during the 1-year study period.

Results: The incidence of cardiac dysfunction was 6% in the study population. Hispanic/Latino patients composed 58% of the study population and represented 50% of patients who experienced cardiotoxicity. Of the patients who developed cardiotoxicity, 50% had hypertension, 25% had hyperlipidemia, 12.5% had type 2 diabetes mellitus, and 12.5% had previous coronary artery bypass grafts. A total of 12.5% had a history of radiation, 25% had a history of anthracycline therapy, 37.5% were former smokers, and 25% were former alcohol users.

Conclusions: The incidence of trastuzumab-related cardiotoxicity in this Hispanic/Latino majority-minority population was 6%, which is surprisingly lower than the 9% cardiotoxicity rate observed in a predominantly white population in a previous study by Otchere et al., in 2023. Further studies are needed to determine the factors contributing to the reduced cardiotoxicity rate observed in this Hispanic population.

Abstract Image

Abstract Image

Abstract Image

曲妥珠单抗诱发的心功能障碍在以西班牙裔为主的南德克萨斯州人群中的发病率和危险因素:一项描述性研究。
背景:曲妥珠单抗是一种针对人表皮生长因子受体2 (HER2)的单克隆抗体,通常是HER2阳性乳腺癌的一线治疗。尽管曲妥珠单抗是有效的,但它具有心脏毒性作用,因此需要通过连续经胸超声心动图(TTEs)进行心脏毒性监测。我们的目的是评估南德克萨斯州人群中曲妥珠单抗相关心功能障碍的危险因素,该人群主要是西班牙裔人群。方法:对2015 - 2021年接受曲妥珠单抗治疗的her2阳性女性乳腺癌患者进行回顾性研究。共发现180例患者。没有基线TTE和基线左心室射血分数(LVEF)小于53%的患者被排除在外。最终样本量包括132名患者。心功能障碍定义为在1年的研究期间LVEF下降超过10%至小于53%。结果:研究人群心功能障碍发生率为6%。西班牙裔/拉丁裔患者占研究人群的58%,占心脏毒性患者的50%。在发生心脏毒性的患者中,50%患有高血压,25%患有高脂血症,12.5%患有2型糖尿病,12.5%曾接受过冠状动脉搭桥手术。其中12.5%有放射史,25%有蒽环类药物治疗史,37.5%曾吸烟,25%曾酗酒。结论:曲妥珠单抗相关心脏毒性在西班牙裔/拉丁裔多数少数人群中的发生率为6%,低于Otchere等人在2023年的一项以白人为主的研究中观察到的9%的心脏毒性发生率。需要进一步的研究来确定在西班牙裔人群中观察到的降低心脏毒性率的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardio-oncology
Cardio-oncology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
5.00
自引率
3.00%
发文量
17
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信